Type 2 diabetes: multimodal treatment of a complex disease
- D. J. Pournaras; C. W. le Roux Type 2 diabetes: multimodal treatment of a complex disease Lancet
Publication Category: Metabolic Health
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
- A. Sudlow; C. W. le Roux; D. J. Pournaras Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy Ther Adv Endocrinol Metab
A prospective randomized controlled trial of lifestyle intervention on quality of life and cardiovascular risk score in patients with obesity and type 2 diabetes
- A. Tuthill; A. Quinn; D. McColgan; M. McKenna; D. O'Shea; T. J. McKenna A prospective randomized controlled trial of lifestyle intervention on quality of life and cardiovascular risk score in patients with obesity and type 2 diabetes Diabetes, obesity & metabolism
Can we predict diabetes remission after weight-loss surgery?
- D. J. Pournaras; C. W. le Roux Can we predict diabetes remission after weight-loss surgery? Lancet Diabetes Endocrinol
Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses
- E. R. McGlone; I. Carey; V. Veličković; P. Chana; K. Mahawar; R. L. Batterham; J. Hopkins; P. Walton; R. Kinsman; J. Byrne; S. Somers; D. Kerrigan; V. Menon; C. Borg; A. Ahmed; B. Sgromo; C. Cheruvu; G. Bano; C. Leonard; H. Thom; C. W. le Roux; M. Reddy; Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses PLoS Med
Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study
- A. D. Miras; L. L. Chuah; N. Khalil; A. Nicotra; A. Vusirikala; N. Baqai; C. Graham; S. Ravindra; G. Lascaratos; N. Oliver; C. W. le Roux Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study Diabetologia
Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses
- E. Molina-Montes; C. Coscia; P. Gómez-Rubio; A. Fernández; R. Boenink; M. Rava; M. Márquez; X. Molero; M. Löhr; L. Sharp; C. W. Michalski; A. Farré; J. Perea; M. O'Rorke; W. Greenhalf; M. Iglesias; A. Tardón; T. M. Gress; V. M. Barberá; T. Crnogorac-Jurce Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses Gut
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- I. Lingvay; P. Sumithran; R. V. Cohen; C. W. le Roux Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation Lancet
Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney Disease
- W. P. Martin; D. Malmodin; A. Pedersen; M. Wallace; L. Fändriks; C. M. Aboud; T. B. Z. Petry; L. P. Cunha da Silveira; A. C. C. da Costa Silva; R. V. Cohen; C. W. le Roux; N. G. Docherty Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney Disease Metabolites
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- C. W. le Roux; A. Astrup; K. Fujioka; F. Greenway; D. C. W. Lau; L. Van Gaal; R. V. Ortiz; J. P. H. Wilding; T. V. Skjøth; L. S. Manning; X. Pi-Sunyer 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet